USPTO serial 98326981
Reviewed by CopyMark Law Group
The USPTO has issued a Notice of Allowance. To complete registration you generally need to file a Statement of Use or an extension request before the deadline.
If you own this trademark, we can monitor new filings and help with USPTO deadlines. If you do not, we can file a new U.S. application.
Plus Government fees of $625
Eveleigh, NSW, AU
Eveleigh, NSW, AU
The USPTO lists this attorney as the applicant's representative for correspondence on this application.
Sydney R. Jensen
Sydney R. Jensen Carr & Ferrell LLP411 Borel Avenue, Suite 603San Mateo, CA 94402United States| Class | Description | Status | First use |
|---|---|---|---|
| 001 | Reagents for scientific or medical research use; enzymes for industrial or scientific purposes; nucleic acid for other than medical and veterinary purposes; nucleic recombinant acid for other than medical and veterinary purposes; acids namely inorganic acids for industrial purposes; DNA polymerase for scientific purposes; chemicals used in environmental monitoring in the nature of chemical preparations for scientific purposes, other than for medical or veterinary use; | ACTIVE | — |
| 005 | Pharmaceutical and veterinary preparations and substances consisting of catalytic DNA molecules being diagnostic reagents and preparations, except for medical or veterinary use for the purpose of detection and identification of pathogens, for the detection of antibiotic resistance, and medical diagnostic reagents for the analysis of body fluids specifically for genotyping, analysis of polymorphisms, detection of acquired or inherited genetic mutations, and for analysis of response to therapy and preparations for detecting and preparations for analysis of gene expression specifically for medical or medical research purposes; reagents for medical and veterinary use; nucleic acid amplification reagents for medical use; nucleic acid sequencing preparations being nucleic acid sequences for medical use; chemical preparations containing enzymes for medical purposes specifically for the diagnosis of diseases or detection or identification of pathogens, for the detection of antibiotic resistance, for the analysis of gene expression, protein expression, metabolic expression, inflammation, and immune-suppression and immune disorders for genotyping, analysis of polymorphisms, detection of acquired or inherited genetic mutations, detection and analysis of epigenetic alterations, analysis of response to therapy; chemical preparations containing enzymes for pharmaceutical, veterinary and medical purposes specifically for the diagnosis of diseases or detection or identification of pathogens, for the detection of antibiotic resistance, for the analysis of gene expression, protein expression, metabolic expression, inflammation, and immune-suppression and immune disorders for genotyping, analysis of polymorphisms, detection of acquired or inherited genetic mutations, detection and analysis of epigenetic alterations, analysis of response to therapy; enzymes for pharmaceutical, veterinary and medical purposes specifically for the diagnosis of diseases or detection or identification of pathogens, for the detection of antibiotic resistance, for the analysis of gene expression, protein expression, metabolic expression, inflammation, and immune-suppression and immune disorders for genotyping, analysis of polymorphisms, detection of acquired or inherited genetic mutations, detection and analysis of epigenetic alterations, analysis of response to therapy; medical kits containing medical diagnostic reagents for testing and analysis of bodily fluids for use in disease detection and/or analysis of pathogens, for the detection of antibiotic resistance, for the analysis of gene expression, protein expression, metabolite expression, inflammation, and immune-suppression and immune disorders, for genotyping; clinical diagnostic preparations for medical or veterinary use, namely, diagnostic preparations for medical or veterinary use; biological chemical diagnostic test kits in the nature of medical diagnostic reagents and assays for testing body fluids for the presence of gene expression, protein expression, metabolite expression, inflammation, immune-suppression, immune disorders; biological chemical test kits containing diagnostic preparations for medical purposes used in medical laboratories in the nature of nucleic acid substrates used for analysis of gene expression, protein expression, metabolite expression, inflammation, immune-suppression, immune disorders | ACTIVE | — |
| 010 | Surgical apparatus and instruments; medical instrument for diagnostic use, namely, apparatus for medical diagnostic testing to diagnose and identify pathogens, infections, and infectious diseases, or other tissue-based diagnostic testing, cytology and cell-based testing specifically for the purposes of analysis of gene expression, protein expression, metabolic expression, inflammation, and immune-suppression and immune disorders for genotyping, analysis of polymorphisms, detection of acquired or inherited genetic mutations, detection and analysis of epigenetic alterations, analysis of response to therapy; medical diagnostic apparatus for diagnosis and identification of, infections, and infectious diseases; diagnostic testing kits consisting primarily of medical diagnostic apparatus and instruments for use in disease detection, namely to diagnose and identify pathogens, infections, and infectious diseases by way of detecting antibiotic resistance, analysis of gene expression, protein expression, metabolic expression, inflammation, and immune-suppression and immune disorders for genotyping, analysis of polymorphisms, detection of acquired or inherited genetic mutations, detection and analysis of epigenetic alterations, and analysis of response to therapy; point of care medical devices, namely, medical apparatus for testing for the detection of antibiotic resistance, for the analysis of gene expression, protein expression, metabolic expression, inflammation, and immune-suppression and immune disorders for genotyping, analysis of polymorphisms, detection of acquired or inherited genetic mutations, detection and analysis of epigenetic alterations, analysis of response to therapy for treatment of infectious diseases, immunological diseases and autoimmune diseases; medical screening kits comprised of medical screening and testing apparatus for the diagnosis of disease, detection and identification of pathogens, for the detection of antibiotic resistance, for the analysis of gene expression, protein expression, metabolic expression, inflammation, and immune-suppression and immune disorders for genotyping, analysis of polymorphisms, detection of acquired and inherited genetic mutations, detection and analysis of epigenetic alterations, analysis of response to therapy | ACTIVE | — |
| 042 | Scientific and technological services and research and design relating thereto, namely, DNA analysis services for scientific research purposes, scientific research consulting in the field of genetics; scientific research in the field of genetics; genetic engineering services for scientific purposes; scientific research in the field of genetics and genetic engineering; scientific research relating to genetics; research relating to chemistry; scientific research relating to chemistry; research in the field of chemistry; product development of medical diagnostic apparatus; design of medical diagnostic apparatus; research relating to molecular sciences; biological, bacteriological, chemical, biochemical, dna, rna, protein, polynucleic acid and molecular analysis and evaluation services to diagnose and identify pathogens, infections, and infectious diseases for medical or scientific research purposes; dna and rna and polynucleic acid and protein sequencing, analysis and evaluation services for scientific purposes; genome sequencing services and the analysis and evaluation of data resulting therefrom in the nature of genetic testing for scientific research purposes; scientific research namely provision of reports relating to scientific and medical experiments, the results of scientific and medical experiments and tests, the analysis and evaluation of scientific and medical data, and data generated by scientific and medical experiments and tests; scientific and medical research and development services in the field of the diagnosis of disease, detection and identification of pathogens, for the detection of antibiotic resistance, for the analysis of gene expression, protein expression, metabolic expression, inflammation, and immune-suppression and immune disorders for genotyping, analysis of polymorphisms, detection of acquired or inherited genetic mutations, detection and analysis of epigenetic alterations, analysis of response to therapy; custom design and development of biochemical assays; | ACTIVE | — |
| 044 | Medical services; human healthcare services; medical testing services relating to the diagnosis and treatment of disease; genetic testing for medical purposes; medical and health care services specifically dna, genetics and genetic testing for medical purposes; medical diagnostic services in the nature of medical testing and medical analysis services for diagnostic purposes provided by medical laboratories; medical diagnostic imaging and molecular medicine being medical services; molecular medical diagnostics testing; | ACTIVE | — |
CopyMark links this record to cited §2(d) serials, the owner's other marks, Nice classes, similar mark names, and recently changed USPTO applications.
| Date | Code | Event | What it means |
|---|---|---|---|
| Apr 2, 2026 | EXRA | NOTICE OF APPROVAL OF EXTENSION REQUEST E-MAILED | — |
| Mar 30, 2026 | EX1G | SOU EXTENSION 1 GRANTED | — |
| Mar 30, 2026 | EXT1 | SOU EXTENSION 1 FILED | — |
| Mar 30, 2026 | EEXT | SOU TEAS EXTENSION RECEIVED | The applicant requested more time to file a Statement of Use before the Notice of Allowance deadline. Each extension typically adds six months. A limited number of extensions are available for intent-to-use applications not yet in use. |
| Oct 7, 2025 | NOAM | NOA E-MAILED - SOU REQUIRED FROM APPLICANT | A Notice of Allowance means your intent-to-use application cleared examination and opposition but is not registered yet. You must file a Statement of Use showing the mark in commerce, or request an extension, before the deadline — usually six months from the notice date. |
| Aug 12, 2025 | NPUB | OFFICIAL GAZETTE PUBLICATION CONFIRMATION E-MAILED | — |
| Aug 12, 2025 | PUBO | PUBLISHED FOR OPPOSITION | Your mark was published in the USPTO Official Gazette for a 30-day opposition window. During that period, third parties who believe they would be harmed can file an opposition. If no opposition is filed, prosecution usually continues toward registration or a Notice of Allowance. |
| Aug 6, 2025 | NONP | NOTIFICATION OF NOTICE OF PUBLICATION E-MAILED | — |
| Jul 7, 2025 | CNSA | APPROVED FOR PUB - PRINCIPAL REGISTER | — |
| Jul 7, 2025 | XAEC | EXAMINER'S AMENDMENT ENTERED | — |
| Jul 7, 2025 | GNEN | NOTIFICATION OF EXAMINERS AMENDMENT E-MAILED | — |
| Jul 7, 2025 | GNEA | EXAMINERS AMENDMENT E-MAILED | — |
| Jul 7, 2025 | CNEA | EXAMINERS AMENDMENT -WRITTEN | — |
| Jun 5, 2025 | DOCK | ASSIGNED TO EXAMINER | — |
| Oct 31, 2024 | TEME | TEAS/EMAIL CORRESPONDENCE ENTERED | — |
| Oct 30, 2024 | CRFA | CORRESPONDENCE RECEIVED IN LAW OFFICE | — |
| Oct 30, 2024 | TROA | TEAS RESPONSE TO OFFICE ACTION RECEIVED | This event means the applicant filed a response to a USPTO Office Action — typically arguments, amendments, or evidence addressing the examiner's objections. The USPTO will review the response and either allow the mark to proceed or issue another action. |
| Jul 30, 2024 | GNRN | NOTIFICATION OF NON-FINAL ACTION E-MAILED | A non-final Office Action means the USPTO examining attorney has raised at least one issue with your trademark application but has not made a final decision. You usually have three months to respond with arguments, amendments, or evidence. Missing the deadline can abandon the application. |
| Jul 30, 2024 | GNRT | NON-FINAL ACTION E-MAILED | A non-final Office Action means the USPTO examining attorney has raised at least one issue with your trademark application but has not made a final decision. You usually have three months to respond with arguments, amendments, or evidence. Missing the deadline can abandon the application. |
| Jul 30, 2024 | CNRT | NON-FINAL ACTION WRITTEN | A non-final Office Action means the USPTO examining attorney has raised at least one issue with your trademark application but has not made a final decision. You usually have three months to respond with arguments, amendments, or evidence. Missing the deadline can abandon the application. |
| Jul 22, 2024 | DOCK | ASSIGNED TO EXAMINER | — |
| Apr 8, 2024 | NWOS | NEW APPLICATION OFFICE SUPPLIED DATA ENTERED | — |
| Dec 21, 2023 | NWAP | NEW APPLICATION ENTERED | — |